About Matrix metalloproteinase-28
Matrix metalloproteinase-28 (MMP28) is a protein
from Homo sapiens identified by UniProt accession
Q9H239, 520 residues long.
MolForge cross-references it against 0 known binders and
135 disease associations.
Target properties
| Protein name | Matrix metalloproteinase-28 |
| UniProt accession | Q9H239 |
| Gene | MMP28 |
| Organism | Homo sapiens |
| Length | 520 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (135)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.25
- genetic disorder · score 0.12
- neoplasm · score 0.09
- immature platelet fraction · score 0.08
- pachyonychia congenita · score 0.08
- hepatocellular carcinoma · score 0.08
- pancreatic adenocarcinoma · score 0.08
- urinary bladder carcinoma · score 0.07
- reticulocyte count · score 0.06
- isolated agammaglobulinemia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9H239-F1 | alphafold | PREDICTED | 81.10 | — |
Amino-acid sequence (520 residues)
MVARVGLLLR ALQLLLWGHL DAQPAERGGQ ELRKEAEAFL EKYGYLNEQV PKAPTSTRFS DAIRAFQWVS QLPVSGVLDR ATLRQMTRPR CGVTDTNSYA AWAERISDLF ARHRTKMRRK KRFAKQGNKW YKQHLSYRLV NWPEHLPEPA VRGAVRAAFQ LWSNVSALEF WEAPATGPAD IRLTFFQGDH NDGLGNAFDG PGGALAHAFL PRRGEAHFDQ DERWSLSRRR GRNLFVVLAH EIGHTLGLTH SPAPRALMAP YYKRLGRDAL LSWDDVLAVQ SLYGKPLGGS VAVQLPGKLF TDFETWDSYS PQGRRPETQG PKYCHSSFDA ITVDRQQQLY IFKGSHFWEV AADGNVSEPR PLQERWVGLP PNIEAAAVSL NDGDFYFFKG GRCWRFRGPK PVWGLPQLCR AGGLPRHPDA ALFFPPLRRL ILFKGARYYV LARGGLQVEP YYPRSLQDWG GIPEEVSGAL PRPDGSIIFF RDDRYWRLDQ AKLQATTSGR WATELPWMGC WHANSGSALF
Explore Matrix metalloproteinase-28 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets